Omada Health swings to a profit and lifts 2026 forecast as members reach 1.1 million
The virtual chronic care company's third-quarter revenue rose 34% to $91.3 million, it earned $6.6 million, and it raised its full-year adjusted EBITDA forecast to $32 million to $34 million.

A year ago, Omada Health lost $3.2 million in the third quarter. This year it earned $6.6 million.
The virtual chronic care company said Nov. 5 that third-quarter revenue rose 34% to $91.3 million from $68.0 million and that total members reached 1.1 million, up 36% from a year earlier. It raised its full-year forecasts for both revenue and adjusted EBITDA.
Why it matters: Omada raised its adjusted EBITDA outlook far more, proportionally, than its revenue outlook. The midpoint of its adjusted EBITDA forecast rose about 38% to $33 million, while the revenue midpoint rose about 2% to $345 million, and gross margin reached 76%, up from 66% a year earlier.
Omada's report came three days after Hinge Health, which also runs a musculoskeletal care program, said its revenue rose 52% and raised its own outlook.
Members and tenure
Enrollment growth was led by its diabetes and hypertension programs, Omada said. It counts as a member anyone enrolled in one of its programs who has produced a billing event within the past 12 months.
Revenue per member over the trailing 12 months grew about 5% to $294. Average member tenure rose 10% to roughly two years and four months, which the company said amounts to about two and a half more months in a program.
Sean Duffy, co-founder and chief executive, called it the company's "strongest quarter yet" in the release.
Profit and cash
Adjusted EBITDA, as the company defines it, was $12.4 million, up from $2.4 million, for a margin of 14% compared with 4%. Omada ended the quarter with $243 million in cash and cash equivalents.
For the first nine months of 2026, revenue was $257.2 million, up from $184.4 million, and net income was $8.9 million, compared with a net loss of $17.9 million. Adjusted EBITDA for the nine months was $24.1 million, versus a loss of $2.0 million on that basis a year earlier.
The business
Omada describes itself as a virtual between-visit care provider for chronic conditions such as obesity, diabetes, hypertension, cholesterol and musculoskeletal conditions. Its model combines care teams, connected devices and software, including support for patients on GLP-1 medications, according to the company. Omada says it has served more than 2 million members since launch through more than 2,000 employers, health plans, pharmacy benefit managers and health systems.
What to watch
Omada now expects 2026 revenue of $344 million to $346 million, up from $334 million to $340 million, which it said would be about 33% growth at the midpoint. It expects adjusted EBITDA of $32 million to $34 million, up from $21 million to $27 million, or about 5.5 times its 2025 level at the midpoint.
Those ranges, set against the nine-month results, imply fourth-quarter revenue of about $86.8 million to $88.8 million and adjusted EBITDA of about $7.9 million to $9.9 million, both below third-quarter levels. The release did not explain the implied step down. Omada did not provide a net income forecast, citing the variability of items excluded from adjusted EBITDA.



